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The complete amino acid sequence of human antileukoprotease has been determined by direct sequencing 
of the inhibitory active protein isolated from seminal plasma (HUSI-I) and by sequence analysis of cDNA 
reverse-transcribed from mRNA prepared from cervical tissue. The inhibitor (Mr 11726) consists of 107 
amino acid residues including 16 cysteines presumably forming disulfide bonds. The molecule comprises 
two consecutive domains which are homologous to each other, to the second domain of the basic protease 
inhibitor from Red Sea turtle (chelonianin) and to both domains of the whey proteins of rat and mouse. 
Both domains contain a pattern of cysteines known as the ‘four-disulfide-core’ that has also been found 
in wheat germ agglutinin and neurophysin. 
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1. INTRODUCTION 
Human mucous fluids, such as seminal plasma, 
cervical mucus, bronchial and nasal secretions and 
tears, contain acid-stable proteinase inhibitors 
with strong affinity for trypsin and chymotrypsin 
as well as for neutrophil lysosomal elastase and 
cathepsin G [l-5]. Isolation of these inhibitors is 
complicated by the occurrence of multiple forms 
probably resulting from limited proteolysis at an 
early stage of sample collection and handling 
[3-71. Most of the secretions contain inflam- 
matory cells including neutrophils liberating 
lysosomal proteinases during their disintegration 
[3,8]. The inhibitors may be further modified by 
limited cleavage(s) when isolated via trypsin or 
chymotrypsin immobilized on a water-insoluble 
matrix [5-81. Limited proteolytic degradation of 
the virgin inhibitor produced and secreted by 
epithelial mucus cells [3] could explain the 
discrepancies between several recent reports on 
biochemical and physicochemical properties of the 
mucus-derived so-called antileukoproteases 
[l-5,9]. 
The antileukoprotease of human seminal 
plasma, HUSI-I (human seminal proteinase in- 
hibitor I), has been most extensively characterized 
[1,6-81. HUSI-I proved to be similar to the an- 
tileukoproteases from other mucous secretions by 
the following criteria: acid stability, inhibition 
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spectrum and molecular mass [3], immunological 
cross-reactivity [3,7,8], amino acid composition [3] 
and partial amino acid sequences [lo]. We have 
now been able to establish the complete amino acid 
sequence of HUSI-I by comparison of protein se- 
quences obtained from inhibitory active material 
with a cloned cDNA sequence reverse-transcribed 
from mRNA isolated from human cervical tissue. 
Surprisingly, HUSI-I shows a close structural 
homology to whey proteins from rat and mouse of 
so far unknown function, and to the basic protease 
inhibitor from Red Sea turtle. 
2. EXPERIMENTAL 
2.1. Isolation of HUSI-I 
HUSI-I was isolated from human seminal 
plasma as described by Schiessler et al. [6,7] and 
further purified by reversed-phase high-per- 
formance liquid chromatography (HPLC) on a 
Supelco LC-18-DB column using a gradient from 
0.05% trifluoroacetic acid in water to 0.05% 
trifluoroacetic acid in acetonitrile. Part of the 
material was repurified by affinity chroma- 
tography on a column of chymotrypsin-Sepharose 
essentially as in [S]. 
2.2. Amino acid sequence analysis 
S-carboxymethylation of the reduced inhibitor, 
performic acid oxidation, cyanogen bromide 
cleavage, citraconylation and cleavage with trypsin 
were performed following standard protocols. 
Peptides were separated by gel chromatography on 
Bio-Gel P-30 in 50% acetic acid (cyanogen 
bromide fragments) or Sephadex G-50 in 0.1 M 
ammonium bicarbonate (tryptic fragments) 
followed by reversed-phase HPLC using a similar 
system as described above. 
Amino acid sequences were determined by 
automated solid-phase Edman degradation in a 
non-commercial sequencer performing on-line 
detection of the released amino acid phenylthio- 
hydantoin derivatives (PTH) by HPLC. Prior to 
sequencing the peptides were coupled to p- 
phenylene diisothiocynate-activated aminopropyl 
glass and/or to aminopropyl glass using hydroxy- 
benzotriazole-catalysed carbodiimide activation in 
anhydrous dimethyl formamide following the pro- 
cedures described [ 111. 
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2.3. cDNA cloning and sequence analysis 
mRNA was prepared from human cervix uteri 
tissue samples, enriched by oligo(dT) chroma- 
tography and reverse-transcribed into cDNA [ 121. 
The double-stranded cDNA was tailed with dCTP 
and annealed to the plasmid pBR322 dG-tailed at 
its PstI site. After transformation of E. coli DH 1 
strain [ 131 the tetracycline-resistant colonies were 
screened by colony hybridisation [14] with a 
chemically synthesized deoxyoligonucleotide 
(mixed probe) derived from the C-terminal portion 
of the known protein sequence. From the plasmid 
DNA of the positive colonies PstI fragments were 
prepared, subcloned into pUC 18 and sequenced by 
the Maxam and Gilbert technique. Details of this 
work will be published separately (Heinzel, R. et 
al., in preparation). 
2.4. Sequence comparisons 
Sequence comparisons with the contents of the 
Protein Sequence Database provided by the 
National Biomedical Research Foundation, 
Washington, DC (released on 25 February 1985) 
were made with a VAX computer using the 
SEARCH and RELATE programs [15]. 
3. RESULTS 
3.1. Amino acid sequence determination 
Sequence analysis (fig.1) revealed that the 
isolated active inhibitor was not an intact polypep- 
tide chain but rather consisted of 2-3 preformed 
proteolytic fragments. A mixture of two parallel 
sequences tarting with Ser (n-l) and Tyr (n-2) was 
obtained by direct Edman degradation of this 
material. N-terminal sequencing of the performic 
acid-oxidized inhibitor yielded a mixture of the 
same two sequences (p-l, p-2) plus an additional 
sequence obviously resulting from acidolytic 
cleavage of the labile Asp-49-Pro-50 peptide bond 
(p-3). Attempts to separate the preformed pro- 
teolytic fragments by gel filtration and reversed- 
phase HPLC were only partially successful. A pure 
fragment was obtained, however, comprising the 
N-terminus of the inhibitor molecule (p-4). A 
second pure fragment yielded a homogeneous 
sequence xtending from Met-73 to close to the C- 
terminal end of the molecule (c-3). 
The sequence of residues 36-107 was deter- 
mined from tryptic fragments (t-l-t-5) of the per- 
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5 10 15 20 25 
Ser-Gly-Lys-Ser-Phe-Lys-Ala-Gly-Val-Cys-Pro-Pro-Lys-Lys-Ser-Ala-Gln-Cys-Leu-Arg-Tyr-Lys-Lys-Pro-Glu- 
n-l o___o_______o___o___o___o___o___o_______o___o_______o___o___o___o_______o 
n-2 o___o___o___o___o__ 
P-l o___________o___o___o___o___o___o_______ o_______o_______o___o___o_______o___o___o___o_______o______ 
P-2 
o___o_______o___o__ 
P-4 o___o___o___o___o_______o___o___o_______o___o___________o___o 
DNA Ser-Gly-Lys-Ser-Phe-Lys-Ala-Gly-Val-Cys-Pro-Pro-Lys-Lys-Ser-Ala-Gln-Cys-Leu-Arg-Tyr-Lys-Lys-Pro-Glu- 
TCT GGA AAG TCC TTC AAA GCT GGA GTC TGT CCT CCT AAG AAA TCT GCC CAG TGC CTT AGA TAC AAG AAA CCT GAG 
30 35 40 45 50 
-Cys-Gln-Ser-Asp-Trp-Gln-Cys-Pro-Gly-Lys-Lys-Arg-Cys-Cys-Pro-Asp-Thr-Cys-Gly-Ile-Lys-Cys-Leu-Asp-Pro- 
n-2 ______o___o___o___o___o_______o___o___o_______o___________o 
p-1 --____o___o 
p_2 ______o___ ~___~_______~_______~_______~ 
o-- 
~___~_-_~___~___~___~___~___~___~___~___~___~___~___~___~__ 
b-l o-- 
DNA -Cys-Gln-Ser-Asp-Trp-Gln-Cys-Pro-Gly-Lys-Lys-Arg-Cys-Cys-Pro- 
TGC CAG AGT GAC TGG CAG TGT CCA GGG AAG AAG AGA TGT TGT CCT 
55 60 65 70 75 
-Val-Asp-Thr-Pro-Asn-Pro-Thr-Arg-Arg-Lys-Pro-Gly-Lys-Cys-Pro-Val-Thr-Tyr-Gly-Gln-Cys-Leu-Met-Leu-Asn- 
p_3 __o___o___o__-____o-__o___o___o___o___o_______o_________-_o___o___o___o___o___o____-__o_-_o___o___o__ 
t-1 __o___o___o___o___o___o_______o 
t-2 o___o___o___~___o__Lo___o___o___o___o___o___o_-_o___o___o___o__ 
c-3 o___o___o__ 
b-1 _-o__-o___o___o___o___o___o___o___o___o___o___o___~________-__________o___o___o_______o___o 
80 85 90 95 100 
-Pro-Pro-Asn-Phe-Cys-Glu-Met-Asp-Gly-Gln-Cys-Lys-Arg-Asp-Leu-Lys-Cys-Cys-Met-Gly-Met-Cys-Gly-Lys-Ser- 
P-3 __o___o___o___o_______o___o 
t-2 __o___o___o___o___o___o___o__-o__-o__-o___o-__o_-_o 
t-3 o___o___o___o___o___o___o___o___o___o___o 
t-4 o-- 
t-5 o___o___o_-_o___o___o___o-__o_-_o__-o__-o___o__ 
c-3 __o___o___o___o___o___o___o___o___o___o___o_______o___o___o___--______o___o__-o___o-__o___o_____-_o__ 
105 107 
-Cys-Val-Ser-Pro-Val-Lys-Ala 
t-4 __o___o___o___o___o___o___o 
t-5 __o___o___o___o___o___o___o 
c-3 __o_-_o__-o___o 
% 
0 
o---o 
Fig. 1. Amino acid sequence of HUSI-I as obtained by protein and cDNA sequencing. Protein sequences (O---O, 
wherein each ‘0' denotes a residue that was unequivocally identified) were determined by automated Edman 
degradation of the whole inhibitor and its preformed proteolytic fragments (n-l, n-2, p-l, p-2, p-4, c-3), an acidolytic 
fragment (p-3), an acidolytically cleaved cyanogen bromide fragment (b-l), and tryptic fragments of the citraconylated 
inhibitor (t-1-t-5). The C-terminal end was identified by degradation with carboxypeptidases A (CA) and A plus B 
(CAB). Parallel sequences in the N-terminal region (residues l-40) obtained from mixtures of unresolved fragments 
(n-l plus n-2 and p-l plus p-2 plus p-3) were aligned with the aid of the corresponding part of the cDNA-derived 
sequence (DNA). 
formic acid-oxidized and citraconylated inhibitor. 
They were overlapped by an acidolytically cleaved 
cyanogen bromide fragment of the S-carboxy- 
methylated protein (b-l) and the preformed 
chymotryptic fragment mentioned above (c-3). 
The C-terminal end of the inhibitor was confirmed 
by the results of carboxypeptidase digestions (cf. 
fig. 1). 
Unambiguous alignment of the various parallel 
sequences obtained from the N-terminal portion of 
the molecule (residues l-40) was not possible 
without the information derived from the cor- 
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responding cDNA sequence (DNA in fig.1). The fluids in vivo and during the course of sample col- 
cDNA-coded amino acid sequence aligned the lection and the first purification steps (cf. section 
parallel sequences determined from mixtures of in- 1). This view is supported by recent experiments 
completely resolved fragments and is entirely con- showing that isolation of HUSI-I via immobilized 
sistent with the results of direct protein sequenc- anhydrotrypsin or HUSI-I-directed antibodies did 
ing. Furthermore, comparison of the cDNA- not significantly change the protein band pattern 
derived and the direct protein sequences revealed in SDS electrophoresis (unpublished). It seems that 
that the cloned piece of cDNA codes for the total limited degradation of the inhibitor in vivo cannot 
HUSI-I protein including a 25residue leader se- be avoided, causing extreme difficulties in the 
quence preceding the sequence of the mature pro- isolation of protein-chemically homogeneous 
tein. The codon for the C-terminal Ala residue of material in amounts sufficient for detailed 
HUSI-I is followed by a stop codon (unpublished). biochemical and structural studies. 
4. DISCUSSION 
4.1. Homogeneity of isolated active in~i~ifor 
preparations 
The HUSI-I preparation isolated in several 
batches could be reproducibly separated into 4 
major and some minor inhibitory active forms. 
The major forms appeared homogeneous by the 
criteria of gel and ion-exchange chromatography, 
end-group analysis and polyacryl~ide gel electro- 
phoresis [6,7]. However, after reduction and sep- 
aration in SDS gel electrophoresis a similar pat- 
tern of bands was always obtained corresponding 
to molecular masses of approx. 10.8 kDa (major 
band mostly) as well as 5.7, 4.3 and 3.4 kDa [7]. 
Obviously the secreted virgin inhibitor molecule is 
already proteolytically modified in the mucous 
In view of these difficulties our approach was 
the combination of protein sequence data obtained 
from a mixture of multiple inhibitory active forms 
with the amino acid sequence derived from a 
cloned fragment of cDNA transcribed from 
mRNA isolated from cervical tissue. This strategy 
enabled us to elucidate the complete amino acid se- 
quence of mature HUSI-I. Furthermore, the cor- 
respondence of the cDNA-derived and directly 
determined amino acid sequences indicates that the 
inhibitor synthesized in the cervical glands is struc- 
turally the same as that isolated from seminal 
plasma. From the close similarity of these in- 
hibitors to the antileukoprotease from bronchial 
secretion 12-5, lo] it can be expected that the latter 
inhibitor has basically the same structure, and very 
probably this also holds true for the an- 
tileukoproteases found in nasal secretion, tears 
HUSI l- 29 
HUSI 5% 83 
HUSI 30- 54 W Q C P a K K R 
a HUSI 84-107 G Q .,. $$ R D L lr: 
WPR 33- 53 E E " A Q N D M 
WPR 87-118 cl $9 :.s~I~TM@ 
RTPI 64-110 s && g fj G Q 1$ 
-&PTVVSFQ 
Fig.2. Sequence homologies between the two domains of HUSI-I, the two internal repeats of rat whey phosphoprotein, 
WPR [ 161, and the second domain of the basic protease inhibitor of Red Sea turtle, RTPI [ 181. Residues identical among 
the internal repeats are boxed, sequence identities among the 3 proteins are shaded. Gaps (indicated by dashes) have 
been allowed to improve the alignment. 
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and the gut [3,8]. It may be assumed that the 
HUSI-I-type antileukoproteases found in human 
mucous secretions are encoded by a single gene ex- 
pressed in all mucus epithelial cells. 
The HUSI-I sequence contains two consecutive 
domains of equal length which are homologous to 
each other (fig.2) suggesting that the present in- 
hibitor has evolved by duplication of a single 
ancestral gene. Both domains contain the same 
characteristic pattern of 8 cysteine residues (see 
below), all of which are presumably involved in 
disulfide bonds. No direct experimental evidence is 
yet available for the location of the reactive site(s) 
on the two domains. Most probable candidates for 
PI and Pri residues are Arg-20-Tyr-21 (first do- 
main) and Leu-72-Met-73 or Met-73-Leu-74 
(second domain) where limited cleavage of the in- 
hibitor has been observed. Qne may speculate that 
these residues are part of an antitryptic site in the 
first domain and an anti-eiastol~ic and/or an- 
tichymotryptic site in the second domain. 
4.3. Sequence ~~~oio~ of WCrS&I with whey 
proteins and the basic protease inhibitor from 
Red Sea turtle 
A computer search revealed si~ni~cant sequence 
homologies of HUSI-I with whey proteins of rat 
1161 and mouse [ 171 and with the second domain of 
the basic protease inhibitor from the Red Sea tur- 
tle, also known as chelonianin [IS]. A striking 
identity is found in the pattern of cysteine residues 
(fig.%). Besides in chelonianin and whey proteins, 
a similar arrangement of cysteines has been found 
in several proteins of different (or unknown) 
biological function such as wheat germ a~lutinin, 
snake neurotoxins, ragweed pollen allergen Ra5, 
and neurophysin. The so-called ‘four-disulfide 
core’ seems to be a common pattern of cysteine 
residues forming a typical 3-dimensional fold of 
disulfide loops which is supposed to stabilize a do- 
main too small to have a sufficient hydrophobic 
core [19]. The possibility that these structures may 
be involved in binding to a membrane-bound 
receptor molecule should also be considered for 
the antiieukoproteases. 
Chelonianin is a two-domain protein&se in- 
hibitor, the first domain being of the Kunitz type 
whereas the second, subtilisin-inhibiting domain 
could not be assigned to any of the existing in- 
hibitor families Il8J. It is this second domain that 
is homologous to the two domains of HUSI-I and, 
as was known before [16], to both domains of the 
whey proteins. Attempts to detect an inhibitory ac- 
tivity of rat whey protein have failed f16). This 
would be consistent with the fact that practically 
no homology with HUSI-I is found in the putative 
active-site regions, but the target enzymes of the 
whey proteins may be different from the pro- 
teinases so far tested. 
In conclusion, HUSI-I is a two-domain inhibitor 
constituting a new family of protein inhibitors of 
proteinases also comprising the second domain of 
chelonianin. An outstanding structural feature of 
this new inhibitor family is the pattern of cysteine 
residues underfying the four-disulfide core and 
shared with a group of small proteins of very dif- 
ferent biological function. 
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